Company
Portfolio Data
Back to Company SearchCHROMOLOGIC LLC
UEI: D9EVNTKKWLF3
Number of Employees: 35
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
SBIR/STTR Involvement
Year of first award: 2007
60
Phase I Awards
33
Phase II Awards
55%
Conversion Rate
$11,131,499
Phase I Dollars
$37,972,053
Phase II Dollars
$49,103,552
Total Awarded
Awards
Membrane-based AWE Device (MAWED)
Amount: $249,907 Topic: HR0011SB20244-02
In order to meet DARPA need, ChromoLogic LLC (CL) proposes developing a Membrane-based AWE Device (MAWED) to ensure a consistent supply of potable water as a distributable system. Unlike traditional cooling-condensing and absorption/desorption methods, MAWED uses an energy-efficient vapor capture and passive condensing approach, combined with a compact, high-surface-area design to meet DARPA requirements. When integrated, MAWED has a dimension size of 72×94×71 cm3 (L×W×H) with energy consumption of 74.6 Wh to generation 1 L potable water at 40 °F 30% RH. The energy consumption decreases with increasing temperature and humidity. Its straightforward design makes it a plug-and-play system, eliminating the need for complex sensors and control systems. Water is captured through diffusion and capillary effect, preventing contamination from the ambience and the capturing process. Additional water purification components eliminate potential biological contamination from long-term storage. Furthermore, the mineralization filter enhances the water's health by adding minerals. In Phase I, CL will fabricate a small prototype for the proof of concept. In Phase II, a high-fidelity full-size prototype will be prepared and demonstrated at DARPA facilities.
Tagged as:
SBIR
Phase I
2025
DOD
DARPA
Ceramic membrane based portable oxygen generator (CEMPOG)
Amount: $1,299,868 Topic: DHA211-009
In order to address this urgent need, ChromoLogic LLC (CL) proposes to develop a ceramic membrane based portable oxygen generator (CEMPOG) to support the supply of medical grade oxygen for forward surgical teams. Unlike the regular membrane separation process, CEMPOG adopts mixed ionic–electronic conducting (MIEC) ceramic membrane to generate ultrapure O2 from ambient air, in which the oxygen molecules absorbed on the membrane surface are catalytically disassociated in oxygen ions and the ions diffuse through the oxygen vacancies of perovskite oxides under a pressure gradient followed by recombination of ions and desorption of oxygen molecules on the permeate. The CEMPOG Phase I prototype exhibited capability to provide 95.6% O2 with ambient air as the only feedstock. Electric current is assigned to direct heat membrane surface up to 900 ºC to initialize and maintain the reaction. To control the energy consumption for pre-heating input air and entire HFM reactor, heat exchangers are applied to cool the product temperature down to 35 ºC.
Tagged as:
SBIR
Phase II
2025
DOD
DHA
Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotic LR-IFN-β
Amount: $1,015,000 Topic: NIAID
Abstract We have developed a genetically modified second-generation probiotic for the localized delivery of a known mitigator to the GI tract in order to reduce damage and regenerate tissue after exposure to ionizing radiation. Mitigating the effects of ionizing radiation exposure is critical for improving survival in the event of a radiological or nuclear (RAD-NUC) incident, where exposure could lead to hematopoietic or gastrointestinal (GI) acute radiation syndrome (ARS). While Neupogen and Neulasta have been granted label extensions by the FDA to treat casualties of a RAD-NUC incident, these drugs do not prevent GI-ARS-related mortality. There currently are no FDA-approved mitigators for GI-ARS. To address this critical need, we have engineered Limosilactobacillus reuteri to produce the therapeutic cytokine INF-β and target the mitigator to the small intestines to recover intestinal stem cells, regenerate the radiation-sensitive intestinal crypts, and dramatically improve survival from 0–10% to 70–80% after exposure to GI-ARS-inducing radiation doses. This is a new strategy for therapeutic drug delivery, using a probiotic that can be administered orally, facilitating its use in the context of a resource-limited mass casualty scenario. In addition to mitigating injury following a RAD-NUC incident, this approach is also applicable to radioprotection of the intestine during abdominal radiotherapy. Symptoms of GI toxicity affect 60–80% of the >300,000 patients that receive pelvic or abdominal radiation therapy per year. This project is based on an entirely new concept that addresses the fundamental major limitations associated with delivery of any potential radiation mitigator of GI syndrome, including (i) non-invasive administration, (ii) targeted delivery of the therapeutic, (iii) maintained bioavailability of the therapeutic at efficacious dose, (iv) trivially scalable to produce, and (v) no need for formulation. The goal of this project is to develop an FDA-approved mitigator for radiation-induced GI injury. We propose critical studies to characterize the radiation dose response, establish the pharmacodynamics of the drug, and characterize the mechanism of drug release in the intestine. These studies are in response to FDA feedback and are aligned with drug approval under the Animal Rule. Successful completion of this work will place this probiotic drug on a strong path towards eventual FDA approval.
Tagged as:
STTR
Phase II
2025
HHS
NIH
Wearable Heat Related Injury Risk Analysis (WHERA) system Resubmission
Amount: $306,469 Topic: NIOSH
PROJECT SUMMARY/ABSTRACT With climate change unfolding, temperature-related illnesses, such as hypothermia and hyperthermia, affect increasing numbers of individuals worldwide every year. Core body temperature has been shown to be a reliable diagnostic of temperature-related illness and its severity, but the current measurement methods are inadequate because they fail to combine minimal invasiveness with high measurement accuracy. Dual-heat flux thermometry is a promising new way of measuring core body temperature at the skin surface, but thus far has lacked precision and compactness due to the limitations of traditional temperature sensing elements. To solve this problem, our team has synthesized thermally sensitive polymers and applied them in a dual-heat flux architecture. By varying the ratio between the polymer building blocks, our team was able to obtain thin films of polymer with thermal resolution of 10 mK. These wearable patches will provide real-time core body temperature information to individuals at risk of temperature-related injury such as firefighters, industrial and farm field workers, military personnel, athletes, as well as to patients requiring core body temperature monitoring for clinical reasons.
Tagged as:
SBIR
Phase I
2025
HHS
CDC
CRISPR-based Assay for Portable Tropical Infection Diagnosis (CAPTIN-D)
Amount: $1,499,763 Topic: 119
Endemic to impoverished regions, neglected tropical diseases and malaria are affecting over a billion peopleworldwide. Malaria gets a special mention, as it threatens populations in 91 countries worldwide, with 241million yearly cases and 627,000 deaths, per WHO’s 2020 report. Even when treatment is available, theinfrastructure of getting the patients diagnosed quickly is inadequate and disintegrated where it is needed themost. This is especially true for complex PCR-based methods. Our solution is a fully self-contained portablein vitro diagnostic device, actuated only by mechanical and chemical potential (no electricity or battery), thatis capable of delivering the sensitivity and specificity of a PCR test, with the simplicity of a rapid diagnostictest. Within the fluidic device, we combined synergistic molecular approaches for nucleic acid extraction, preamplification,and CRISPR-based detection. The intuitive user interface, with build-in controls and visualcues of the assay will make the assay simple enough to self-administer and interpret for the user. Our PhaseI prototypes reached the sensitivity of 10 parasites/ìL during the 1-hour long assay on P.falciparum culturesin blood. In Phase II, we are expanding our diagnostic capabilities to allow for Plasmodium genotyping aswell as detection of other tropical parasites.
Tagged as:
SBIR
Phase II
2025
HHS
NIH
SBIR Topic 134: Alternatives to Benzathine Penicillin for Treatment of Syphilis
Amount: $299,914 Topic: 134
Syphilis is a sexually transmitted disease caused by T. pallidum. The WHO estimates that 7.1 million persons aged 15-49 acquired syphilis in 2020. Benzathine penicillin (BPG) is the only CDC recommended treatment for syphilis. However, recently shortages of this medicine have been reported worldwide. In addition, BPG is given intramuscularly by injection, which makes it difficult to be administered in countries or regions where proper medical facilities or qualified personnel are not available. To address this, ChromoLogic LCC will develop the Lipophilic Conjugates of Tetracycline as Alternatives to Penicillin G for Syphilis Treatment (LC-TAPS). The LC-TAPS are designed to exhibit improved pharmacokinetics and biodistribution compared to tetracyclines drugs. The minimal inhibitory concentration (MIC) for T. pallidum treated with these three LC-TAPS compounds developed will be determined. It is expected that LC-TAPS will have lower MIC values for T. pallidum compared to tetracyclines. The toxicity of the three LC-TAPS toward the host rabbit cells will be also evaluated. The fluorescent properties of LC-TAPS will be utilized to determine their localization, their cellular uptake and biodistribution in human and rabbit cells. These studies will determine the affinity of LC-TAPS antibiotics for these cells.
Tagged as:
SBIR
Phase I
2024
HHS
NIH
Membrane Contactor based CO2 Absorbing Module (MC-CAM)
Amount: $1,999,834 Topic: N222-120
In order to meet Navy’s need, ChromoLogic LLC (CL) proposes to develop a Membrane Contactor based CO2 Absorbing Module (MC-CAM) to maintain CO2 concentration of CCR in a safe range (<0.4%). The expected outcome is that MC-CAM system will be integrated smoothly into the existing SCUBA systems providing endurance for over 10 hours. The innovative microstructure, high surface area to package volume ratio, and novel catalyst application enable the design to be compacted to at least 60% of the commercial canisters. The MC-CAM is ruggedized and reusable, primarily based on physical absorption, and designed to protect divers from hypercapnia without any preventive maintenance. The proposed concept has been validated in Phase I and a high-fidelity full-size prototype will be fabricated and demonstrated at Navy facility.
Tagged as:
SBIR
Phase II
2024
DOD
NAVY
Microorganisms Genome Enrichment and Amplification Sequencing (MGEAS)
Amount: $846,741 Topic: S13
Recent evidence shows that the cleanrooms of Jet Propulsion Laboratory environments, such as floors and hardware surfaces, could harbor various microorganisms, and a comprehensive metagenomics framework to characterize organisms relevant to planetary protection is needed. Current metagenomics practices for microbe detection in low biomass samples generally do not fit well with NASA needs, due to high requirements in DNA concentration, small sample processing volumes, variability, and high predictive errors. MGEAS addresses these issues with three modules (1) A sampling or filtration unit that process larger volumes of input solutions, (2) DNA preparations, enrichment, and amplifications followed by NGS sequencing, (3) Bioinformatics pipeline optimization for reads classification and genome assembly. As part of the phase I project ChromoLogic i) successfully evaluated two state-of-the-art genome amplification or enrichment techniques for NGS library preparation. ii) optimized kmers and various bioinformatics parameters for microbial taxa classification based on raw reads and iii) provided taxa reports for JPL environmental samples (wipes and swabs) and identified taxa with radiation, disinfectant resistance. In Phase II we propose to combine our achievements with a) the novel use of SMART accessory blocks for lab-work automations, and various techniques to improve nucleic acids yield and assay repeatability, b) state of the art DNA preparations, enrichment and amplifications followed by NGS sequencing, and c) Bioinformatics pipeline optimization for reads classification, genome assembly and adjacent DNA linked reads sequencing (Hi-C) for radiation/disinfectant resistant elements origin tracing (in species and environments). We will also expand our statistical modeling tests to improve accuracy and sensitivity of assays to fit NASA needs and we will build interactive software visualization tools for easier user navigation of taxa data and sample statistics.
Tagged as:
SBIR
Phase II
2024
NASA
NGS based metagenomic screening of ocular infections
Amount: $1,701,925 Topic: NEI
Project Summary/Abstract: The project objective is to develop an organism-agnostic deep sequencing-based diagnosis of ocular infectious disease from microliter-sized biopsies in less than 24 hours and for less than $1000. Current diagnostic approach relies on bacterial and fungal cultures that are time-consuming (~2-3 days) and often leads to the overuse of broad-spectrum antibiotics. In Phase I, we successfully developed and validated the EYE-Path™ system, demonstrating an integrated Scalable Metagenomics Alignment Research Tool (SMART) with an automated DNA extraction system for sample preparation. This system achieved a low limit of detection (104 cells/mL) and a turnaround time of <3 hours for bacterial infections. In Phase II, we plan to optimize the adaptive sequencing software for the SMART Adapt algorithm, validate the system in a multi-site clinical study (University of California, Los Angeles and University of Washington) in patients with corneal ulcer and suspected endophthalmitis, validate the system as a CLIA ready test and initiate a pre-submission meeting with the FDA to determine the appropriate regulatory strategy for eye-PATH to be considered as a CLIA waived in vitro-diagnostic device. The success completion of this project could significantly impact ocular infection diagnosis and treatment planning, with broader applications in point-of-care devices and non-ophthalmic diagnostics, helping to combat antimicrobial resistance.
Tagged as:
STTR
Phase II
2024
HHS
NIH
Rapid, Portable, Surface Texture Based Component Classifier (RAPSTEC) System
Amount: $1,699,887 Topic: DMEA192-002
In order to address these urgent DOD needs, ChromoLogic LLC (CLL) has developed (TRL 6) a Rapid, portable, surface texture based component classifier (RAPSTEC) system that will rely on a machine learning based algorithm to instantly identify a) if a microelectronic component has been re-marked, which is the most common form of microelectronic counterfeiting and/or b) if the component is a clone that was not produced by the original component manufacturer (OCM) and c) create a virtual tag (vTag®) for each component extracted from a PCB so that it can be accurately be re-populated. RAPSTEC leverages the fact that all components, at the micrometer scale, have unique and random surface texture that is intrinsic, immutable, unforgeable and covert. The surface texture of a component, while completely random and unique to the part itself, also represents the manufacturing process (such as the injection mold or polishing technique) that was used to produce the part. These features, because they are at a micrometer scale, cannot be replicated. We have exploited this fundamental fact of nature and developed a range of commercial products based on our patented (Characterization of a Physical Object based on its Surface Roughness, US 10,341,555) hardware platform that uses surface texture to a) uniquely fingerprint a component and/or b) determine if a components surface has been modified. These products are available through our wholly owned subsidiary, Covisus Inc. (www.covisus.com).
Tagged as:
SBIR
Phase II
2024
DOD
DMEA